{
    "root": "31554477-2944-6b1d-e063-6294a90a3a9f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "celecoxib",
    "value": "20250327",
    "ingredients": [
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE",
            "code": "RFW2ET671P"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        }
    ],
    "indications": "Celecoxib capsules are indicated",
    "contraindications": "• Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals ( 2.1 ) • OA: 200 mg once daily or 100 mg twice daily ( 2.2 , 14.1 ) • RA: 100 mg to 200 mg twice daily ( 2.3 , 14.2 ) • JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg ( 2.4 , 14.3 ) • AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit ( 2.5 , 14.4 ) • AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers, ( 2.7, 8.8 , 12.3 ).",
    "warningsAndPrecautions": "Celecoxib Capsules 100 mg\n  \n                     \nSize '4', White opaque cap, white opaque body with 'C5' imprinted on the blue band on the cap and '100mg' imprinted on the blue band on the body and are available as follows:\n  \n                     \nBottles of 1 Capsule  NDC 76420-243-01 (repackaged from NDC 33342-156-XX)\n  \n                     \nBottles of 7 Capsules NDC 76420-243-07 (repackaged from NDC 33342-156-XX)\n \n                  Bottles of 20 Capsules NDC 76420-243-20 (repackaged from NDC 33342-156-XX)\n  \n                     \nBottles of 30 Capsules NDC 76420-243-30 (repackaged from NDC 33342-156-XX)\n \n                  Bottles of 60 Capsules NDC 76420-243-60 (repackaged from NDC 33342-156-XX)\n                  Bottles of 90 Capsules NDC 76420-243-90 (repackaged from NDC 33342-156-XX)\n                  \n                     \n                        Storage \n                     Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions": "• Celecoxib capsules are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [\n       \n \n  \n       \n \n  see Warnings and Precautions (\n        \n  \n   \n        \n  \n   5.7, \n        \n  \n   \n        \n  \n   5.9)\n       \n \n  \n       \n \n  ]. \n       \n \n  \n       \n \n   • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients [\n       \n \n  \n       \n \n  see Warnings and Precautions (\n        \n  \n   \n        \n  \n   5.7, \n        \n  \n   \n        \n  \n   5.8)\n       \n \n  \n       \n \n  ]. \n       \n \n  \n       \n \n   • In the setting of CABG surgery [\n       \n \n  \n       \n \n  see Warnings and Precautions (\n        \n  \n   \n        \n  \n   5.1)\n       \n \n  \n       \n \n  ]. \n       \n \n  \n       \n \n   • In patients who have demonstrated allergic-type reactions to sulfonamides."
}